NasdaqCM:CLDX

Stock Analysis Report

Executive Summary

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Celldex Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLDX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.8%

CLDX

3.5%

US Biotechs

2.4%

US Market


1 Year Return

-64.2%

CLDX

4.6%

US Biotechs

-10.0%

US Market

Return vs Industry: CLDX underperformed the US Biotechs industry which returned -0.9% over the past year.

Return vs Market: CLDX underperformed the US Market which returned -15.1% over the past year.


Shareholder returns

CLDXIndustryMarket
7 Day4.8%3.5%2.4%
30 Day-30.4%-3.2%-11.0%
90 Day-32.8%-2.4%-19.4%
1 Year-64.2%-64.2%5.4%4.6%-8.1%-10.0%
3 Year-96.5%-96.5%19.3%16.3%17.3%9.6%
5 Year-99.6%-99.6%-4.4%-8.9%36.1%21.1%

Price Volatility Vs. Market

How volatile is Celldex Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Celldex Therapeutics undervalued compared to its fair value and its price relative to the market?

0.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CLDX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CLDX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CLDX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CLDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLDX is good value based on its PB Ratio (0.3x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Celldex Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-9.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLDX's revenue (15.4% per year) is forecast to grow faster than the US market (7.1% per year).

High Growth Revenue: CLDX's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLDX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Celldex Therapeutics performed over the past 5 years?

9.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLDX is currently unprofitable.

Growing Profit Margin: CLDX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLDX is unprofitable, but has reduced losses over the past 5 years at a rate of 9.1% per year.

Accelerating Growth: Unable to compare CLDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: CLDX has a negative Return on Equity (-54.11%), as it is currently unprofitable.


Next Steps

Financial Health

How is Celldex Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CLDX's short term assets ($66.7M) exceed its short term liabilities ($11.6M).

Long Term Liabilities: CLDX's short term assets ($66.7M) exceed its long term liabilities ($17.3M).


Debt to Equity History and Analysis

Debt Level: CLDX is debt free.

Reducing Debt: CLDX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CLDX has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 6.7% each year.


Next Steps

Dividend

What is Celldex Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CLDX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Anthony Marucci (57yo)

11.58s

Tenure

US$1,385,351

Compensation

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. Mr. Marucci Founded Celldex Therapeutics Inc. in May 2003. Mr. Marucci  ...


CEO Compensation Analysis

Compensation vs Market: Anthony's total compensation ($USD1.39M) is above average for companies of similar size in the US market ($USD618.59K).

Compensation vs Earnings: Anthony's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Anthony Marucci
Founder11.58yrsUS$1.39m0.025% $7.7k
Tibor Keler
Founder16.92yrsUS$748.71k0.013% $4.1k
Sam Martin
Senior VP2.75yrsUS$622.25k0.0056% $1.7k
Elizabeth Crowley
Chief Product Development Officer & Senior VP5.75yrsUS$585.71k0.0028% $850.1
Margo Heath-Chiozzi
Senior Vice President of Regulatory Affairs2.5yrsUS$602.75kno data
Sarah Cavanaugh
Senior Vice President of Corporate Affairs & Administration2.83yrsno data0.0018% $550.4
Ronald Pepin
Chief Business Officer & Senior VP8.75yrsno datano data
Richard Wright
Chief Commercial Officer & Senior VP4.75yrsUS$563.17k0.0012% $360.8
Diane Young
Senior VP & Chief Medical Officer0.75yrno datano data

4.8yrs

Average Tenure

57yo

Average Age

Experienced Management: CLDX's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anthony Marucci
Founder11.58yrsUS$1.39m0.025% $7.7k
Harry Penner
Independent Director23.25yrsUS$93.59k0.013% $4.1k
Herbert Conrad
Independent Director12.08yrsUS$91.84k0.012% $3.7k
Louis Weiner
Member of Scientific Advisory Boardno datano datano data
James Marino
Independent Director3.08yrsUS$90.47k0.022% $6.9k
Karen Shoos
Independent Director18.92yrsUS$88.22k0.013% $4.1k
Carl June
Member of Scientific Advisory Boardno datano datano data
Jeffrey Weber
Member of Scientific Advisory Boardno datano datano data
Randolph Noelle
Member of Scientific Advisory Boardno datano datano data
Keith Brownlie
Independent Director2.83yrsUS$94.22k0.0013% $385.3

11.7yrs

Average Tenure

67yo

Average Age

Experienced Board: CLDX's board of directors are seasoned and experienced ( 11.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.9%.


Top Shareholders

Company Information

Celldex Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Celldex Therapeutics, Inc.
  • Ticker: CLDX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$30.580m
  • Shares outstanding: 17.57m
  • Website: https://www.celldex.com

Number of Employees


Location

  • Celldex Therapeutics, Inc.
  • Perryville III Building
  • Suite 220
  • Hampton
  • New Jersey
  • 8827
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLDXNasdaqCM (Nasdaq Capital Market)YesCommon Stock with Par Value 0.001USUSDMar 2008
TCE2DB (Deutsche Boerse AG)YesCommon Stock with Par Value 0.001DEEURMar 2008
0HUULSE (London Stock Exchange)YesCommon Stock with Par Value 0.001GBUSDMar 2008

Biography

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 03:37
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.